News from Futu News on December 20, this Monday $SIRNAOMICS-B (02257.HK)$The announcement was announced that it will issue 7.54 million shares from December 20 to 23. The company plans to issue 7.54 million shares, including 754,000 shares for public sale and 6.786 million shares for international sale, with an issue price of HK$65.9-72.7, and 50 shares per lot. It is expected to be listed on December 30.
Shengnuo Pharmaceutical is an RNA therapy biopharmaceutical company. Its candidate products are in the preclinical and clinical stages, focusing on exploring and developing innovative drugs to treat indications with medical needs and huge market opportunities. The company was founded in 2007 when Sirnaomics was founded in the US. Currently, it has market positions in both China and the US, and has R&D centers in both countries.
The company's core product, STP705, has proven efficacy and safety in phase I/II clinical trials of non-melanoma skin cancer, and will further advance STP705 for squamous cell carcinoma in situ (isSCC) in phase IIb clinical trials, phase II clinical trials for treating skin basal cell carcinoma (BCC), phase II clinical trials for treating keloids, and phase I/II clinical trials for proliferative scarring (HTS). At the last practical date, the two US authorized patents and seven pending patent applications covered the company's core product STP705, including 2 from China and 5 from the US.
Finance...